Literature DB >> 27086350

Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma.

Shinichi Makita1,2, Dai Maruyama3, Akiko Miyagi Maeshima4, Hirokazu Taniguchi4, Ken-Ichi Miyamoto1, Hideaki Kitahara1, Suguru Fukuhara1, Wataru Munakata1, Yukio Kobayashi1, Jun Itami5, Kensei Tobinai1,2.   

Abstract

Hodgkin lymphoma (HL) is a rare subtype of malignant lymphoma in Japan, and there are few reports of HL in Japan in recent years. We retrospectively analyzed the clinical features of 139 patients with HL who were diagnosed and treated at our institution between 1997 and 2011. The median age at diagnosis was 34 years with 83 male. Of these patients, 83 (60 %) were early stage and 56 (40 %) were advanced-stage. Seventy-three patients (88 %) with early stage disease received ABVd followed by irradiation. All of the 56 advanced-stage patients received chemotherapy, mainly ABVd. The 5-year progression-free survival (PFS) rates and overall survival rates were 90 and 94 % in patients with early stage disease, and 71 and 90 % in those with advanced-stage disease. The PFS of patients with advanced-stage disease was significantly lower than those with early stage (p = 0.014). In conclusion, the outcomes of Japanese patients with HL in recent years were not improved as compared with the results of previous reports. We confirmed that patients with advanced-stage disease have lower PFS than those with early stage disease. Prospective studies are needed to establish novel treatment strategies to improve the outcome of HL patients, especially those with advanced disease.

Entities:  

Keywords:  ABVd; Hodgkin lymphoma; Japanese patient

Mesh:

Substances:

Year:  2016        PMID: 27086350     DOI: 10.1007/s12185-016-2007-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  33 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

Authors:  Andres Forero-Torres; Beata Holkova; Jerome Goldschmidt; Robert Chen; Gregg Olsen; Ralph V Boccia; Rodolfo E Bordoni; Jonathan W Friedberg; Jeff P Sharman; Maria Corinna Palanca-Wessels; Yinghui Wang; Christopher A Yasenchak
Journal:  Blood       Date:  2015-09-16       Impact factor: 22.113

3.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

4.  Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD.

Authors:  S Viviani; A Santoro; G Ragni; V Bonfante; O Bestetti; G Bonadonna
Journal:  Eur J Cancer Clin Oncol       Date:  1985-05

5.  Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma.

Authors:  Lois B Travis; Deirdre Hill; Graça M Dores; Mary Gospodarowicz; Flora E van Leeuwen; Eric Holowaty; Bengt Glimelius; Michael Andersson; Eero Pukkala; Charles F Lynch; David Pee; Susan A Smith; Mars B Van't Veer; Timo Joensuu; Hans Storm; Marilyn Stovall; John D Boice; Ethel Gilbert; Mitchell H Gail
Journal:  J Natl Cancer Inst       Date:  2005-10-05       Impact factor: 13.506

Review 6.  Advances in the treatment of Hodgkin lymphoma.

Authors:  Dennis A Eichenauer; Andreas Engert
Journal:  Int J Hematol       Date:  2012-10-11       Impact factor: 2.490

7.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

8.  Twenty years of MOPP therapy for Hodgkin's disease.

Authors:  D L Longo; R C Young; M Wesley; S M Hubbard; P L Duffey; E S Jaffe; V T DeVita
Journal:  J Clin Oncol       Date:  1986-09       Impact factor: 44.544

9.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

10.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

Authors:  Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans-Konrad Müller-Hermelink; Eckhardt Dühmke; Markus Loeffler
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

View more
  8 in total

Review 1.  An Update on the Pathology and Molecular Features of Hodgkin Lymphoma.

Authors:  Akira Satou; Taishi Takahara; Shigeo Nakamura
Journal:  Cancers (Basel)       Date:  2022-05-26       Impact factor: 6.575

Review 2.  Interplay between Epstein-Barr virus infection and environmental xenobiotic exposure in cancer.

Authors:  Francisco Aguayo; Enrique Boccardo; Alejandro Corvalán; Gloria M Calaf; Rancés Blanco
Journal:  Infect Agent Cancer       Date:  2021-06-30       Impact factor: 2.965

3.  Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study.

Authors:  A Amraee; M R Evazi; M Shakeri; N Roozbeh; M Ghazanfarpour; M Ghorbani; J Ansari; L Darvish
Journal:  Clin Transl Oncol       Date:  2019-02-09       Impact factor: 3.340

4.  Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.

Authors:  Dai Maruyama; Kiyohiko Hatake; Tomohiro Kinoshita; Noriko Fukuhara; Ilseung Choi; Masafumi Taniwaki; Kiyoshi Ando; Yasuhito Terui; Yusuke Higuchi; Yasushi Onishi; Yasunobu Abe; Tsutomu Kobayashi; Yukari Shirasugi; Kensei Tobinai
Journal:  Cancer Sci       Date:  2017-05-19       Impact factor: 6.716

Review 5.  Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.

Authors:  Shinichi Makita; Dai Maruyama; Kensei Tobinai
Journal:  Onco Targets Ther       Date:  2020-06-23       Impact factor: 4.147

6.  CD20 expression is closely associated with Epstein-Barr virus infection and an inferior survival in nodular sclerosis classical Hodgkin lymphoma.

Authors:  Xia Zhao; Yushuo Ma; Haiyan Bian; Zhihe Liu
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

7.  An Autopsy Case of an Elderly Patient with Classic Hodgkin Lymphoma Presenting with a Plethora of Clinical Symptoms and Signs.

Authors:  Hiroshi Kobayashi; Ryouya Seki; Masuo Ujita; Kana Hirayama; Satoshi Yamada; Riuko Ohashi; Yoshiro Otsuki; Takuya Watanabe; Tadashi Yoshino
Journal:  Am J Case Rep       Date:  2020-10-22

8.  Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study.

Authors:  Junya Makiyama; Yoshitaka Imaizumi; Haruka Watanabe; Machiko Fujioka; Masahiko Chiwata; Hideaki Kitanosono; Jun Nakashima; Yasushi Miyazaki; Shinichiro Yoshida
Journal:  Intern Med       Date:  2020-10-21       Impact factor: 1.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.